Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report

BACKGROUND: Targeted therapy with anaplastic lymphoma kinase inhibitor alectinib has become standard therapy for selected patients with non-small cell lung carcinoma. Few data are available on the renal effects of alectinib. We report on a case of acute kidney injury in a patient using alectinib for...

Descripción completa

Detalles Bibliográficos
Autores principales: van Londen, Marco, Roosma, Elizabeth, Vogels, Stefanie, van Putten, John W. G., Janssen, Wilbert M. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524124/
https://www.ncbi.nlm.nih.gov/pubmed/36176005
http://dx.doi.org/10.1186/s13256-022-03532-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524124/
https://www.ncbi.nlm.nih.gov/pubmed/36176005
http://dx.doi.org/10.1186/s13256-022-03532-2

Ejemplares similares